Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2020 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2020.102728
Abstract: Background Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbations. The aim of this study was to identify cell free DNA- (cfDNA-) based alterations and their associations with outcomes in… read more here.
Keywords: prostate; ctdna; dna; prostate cancer ... See more keywords
Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.102
Abstract: 102Background: In ARCHES (NCT02677896) ENZA + ADT reduced the risk of radiographic progression-free survival (rPFS) events, primary endpoint, and improved key secondary endpoints vs PBO + ADT in me... read more here.
Keywords: progression; efficacy enzalutamide; enza plus; mhspc ... See more keywords
Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.28.3.287
Abstract: BACKGROUND: Prostate cancer is common among men in the United States, and hormone sensitive-prostate cancer (HSPC) is the predominant etiology. However, there is a paucity of evidence documenting the financial impact of metastatic disease within… read more here.
Keywords: mhspc; care resource; etiology; care ... See more keywords